SM
REGN icon

SG3 Management’s Regeneron Pharmaceuticals REGN Stock Holding History

SG3 Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-200
Closed -$126K – 1305
2021
Q4 		$126K Sell
200
-300
-60% -$184K ﹤0.01% 884
2021
Q3 		$303K Buy
500
+200
+67% +$124K 0.01% 703
2021
Q2 		$168K Buy
+300
New +$152K 0.01% 849

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

SG3 Management's REGN Position: Q1 2022 in Review

SG3 Management sold out of Regeneron Pharmaceuticals (REGN) in Q1 2022, closing a stake of 200 shares — an estimated $126K sold.

SG3 Management first reported a position in REGN in Q2 2021 and held it in 3 quarters. The position peaked at $303K in Q3 2021. 1,095 funds tracked by Wall St. Rank hold REGN as of Q1 2022.

  • SG3 Management reported no remaining Regeneron Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • SG3 Management sold 200 Regeneron Pharmaceuticals shares in Q1 2022, an estimated $126K.
  • SG3 Management first reported a position in Regeneron Pharmaceuticals in Q2 2021 and held it in 3 quarters.
  • SG3 Management's Regeneron Pharmaceuticals position peaked at $303K in Q3 2021.
  • 1,095 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2022.

Based on SG3 Management's 13F filing for Q1 2022, filed 16 May 2022.